Xtant Medical Holdings, Inc.

What they do

Xtant designs, develops and commercializes orthobiologics and spinal implant fixation systems used by orthopedic spine surgeons and neurosurgeons for complex spine, deformity and degenerative procedures in the cervical, thoracolumbar and interbody spine. Its biologics are also used in trauma, foot and ankle, sports medicine, total joint and wound care applications. Products are sold in the U.S. through independent distributors and stocking agents supported by direct employees, with international sales via stocking distributors in Europe, Canada, Mexico, South America and parts of the Pacific region.

Revenue drivers

• Orthobiologics portfolio — Biologics including demineralized bone matrix, synthetic bone graft, collagen and amniotic membrane allografts; marketed under brands such as Trivium, nanOss Strata, CollagenX, OsteoFactor Pro, OsteoVive Plus, SimpliGraft and SimpliMax, and sold through GPO and IDN contracts.
• Spinal implant fixation systems — Hardware products including the Cortera Posterior Fixation System; revenue is largely generated through independent sales agents and distributors, and the 10-K risk factors note this hardware family revenue has declined in recent periods.
• License revenue — The company recognized $18.7 million of license revenue in 2025 tied largely to its SimpliMax product and amniotic membrane agreements; management states this likely will not repeat in 2026 after a January 1, 2026 reimbursement change.
• Divested Coflex/CoFix and international hardware — Sold to Companion Spine on December 1, 2025 for an aggregate purchase price of $21.4 million; generated $20.3 million of 2025 revenue before the sale and, as anticipated, its loss is reducing 2026 revenue.

Recent performance

Second quarter 2026 revenue was $23.0 million versus $35.4 million in the second quarter of 2025, a decline attributed to the December 2025 Companion Spine divestiture and to license revenue that ceased at the end of 2025. Second quarter 2026 gross margin fell to 57.9% from 68.6%, hurt by the loss of high-margin Q-code license revenue, lower production efficiencies and higher excess and obsolete inventory charges. Operating expenses rose to $22.5 million from $19.7 million, primarily due to a $5.0 million exclusivity fee paid to Dilon Technologies, partly offset by lower G&A and sales and marketing costs after the divestiture. The quarter produced a net loss of $9.4 million versus net income of $3.6 million a year earlier, and adjusted EBITDA was a loss of $2.7 million versus positive $6.9 million. At June 30, 2026 the company held $9.9 million of cash, $23.0 million of total indebtedness and $0.7 million of revolver availability.

Strategy

Management is pursuing four stated growth initiatives: introduce new products, expand the distribution network, penetrate adjacent markets, and use its platform for technology and strategic acquisitions. Recent product introductions include nanOss Strata, CollagenX, OsteoFactor Pro and Trivium, plus Trivium Shaped launched in the second quarter of 2026. In April 2026 the company signed an exclusive U.S. distribution agreement with Dilon Technologies for the FDA-approved HEMOBLAST Bellows hemostatic agent and hired approximately 20 Dilon sales personnel to sell it alongside Xtant's biologics portfolio. The company also divested non-core Coflex/CoFix assets and its international hardware business to Companion Spine in December 2025 and used part of the proceeds to repay term debt.

Risks

• Non-repeating 2025 license revenue — The $18.7 million of 2025 license revenue likely will not repeat in 2026 after a January 1, 2026 reimbursement change for SimpliMax, which management says will hurt 2026 revenue and gross margins.
• Divestiture-driven revenue decline — The December 2025 sale of Coflex/CoFix and international hardware assets removed $20.3 million of 2025 revenue, and the company states the loss has adversely affected and will continue to adversely affect 2026 revenue.
• Dependence on independent agents for hardware — A substantial portion of hardware product family revenue runs through independent sales agents and distributors the company does not control, and that revenue has declined in recent periods.
• Limited liquidity and leverage — At June 30, 2026 the company had $9.9 million of cash, $23.0 million of total indebtedness and only $0.7 million of revolver availability.

Outlook

Management attributes the 2026 revenue decline to the Companion Spine divestiture and the end of 2025 license revenue, and states these losses will continue to adversely affect 2026 revenues, operating results and gross margins compared with 2025. The company expects the Dilon distribution agreement and Trivium Shaped launch to broaden its biologics portfolio and expand hospital and surgeon access, which CEO Sean Browne says positions the company for long-term growth. Xtant historically incurred significant losses, and its risk factors state it expects to continue to incur losses despite generating net income in 2025.